Target AFIB market EPIX Therapeutics focuses on catheter-based ablation for atrial fibrillation using the DiamondTemp system. Sales opportunities exist in physician groups and hospitals expanding AFIB treatment programs, particularly where high-resolution electrogram feedback and temperature sensing can differentiate outcomes.

Regulatory pathway DiamondTemp is currently limited to investigational use in the United States, with CE marking achieved in 2017. Opportunities may arise from institutions participating in IDE-led pivotal trials or from regional markets where clearance has already occurred, enabling faster adoption timelines.

Strategic partnerships Past activity shows participation from established medtech players and large funding rounds. Explore collaboration or distribution agreements with major cardiac device distributors, electrophysiology centers of excellence, or potential acquirers seeking to augment AFIB ablation portfolios.

Financial readiness Company has raised substantial funding ($69M total) and operates with revenue under $1M, indicating a growth-phase opportunity for capital-intensive sales cycles, bundled service agreements, and customized reimbursement strategies aligned with hospital procurement teams.

Value proposition Key differentiators include three capabilities: temperature feedback, low irrigation, and high-resolution electrogram attenuation. Emphasize improved safety and efficacy to drive adoption in centers aiming to reduce procedure time, improve outcome consistency, and differentiate their AFIB programs.